TAGCyx has executed collaborative research agreement with HEALIOS K.K.

TAGCyx has signed collaborative research agreement with HEALIOS K.K. (CEO: Hardy TS Kagimoto, MD, Head office: Tokyo, listed on Tokyo Stock Exchange Mothers Index: 4593), to generate TAGCyx’ innovative DNA aptamers, Xenoligo®.
Based on the terms of the agreement, TAGCyx will generate Xenoligo®, using its proprietary artificial nucleic acid base pair technology in order to contribute the development of HEALIOS’ regenerative medicine and cell therapeutics.
In return, TAGCyx will receive collaborative research fees as well as milestone payments upon successful generation of the aptamers.
Under the confidentiality of the agreement, further details of the research is not disclosed.

Comments are closed.